NEW YORK (GenomeWeb) – Inova said today that it has partnered with Veritas Genetics to provide whole-genome sequencing and interpretation services.
Later this year the companies plan to offer a service called MyMap, which will include MyGenome next-generation sequencing by Veritas and MediMap pharmacogenomic testing by Inova.
Veritas' MyGenome uses NGS to screen a patient's whole genome for more than 1,200 clinically relevant conditions, assess carrier status for over 100 inherited conditions, identify more than 120 traits, and provide genetic ancestral data by region.
Inova's MediMap, meanwhile, analyzes 31 genes that influence response to 145 prescription medications across 14 medication categories.
The MyMap offering will also include genetic counseling from Inova with the aim of translating and interpreting data into meaningful recommendations specific to a patient's DNA. In addition, patients will have access to Inova's network of physician specialists and subspecialists to develop a care plan.
"The information gleaned from a patient's MyMap report can create a lifetime of useful information that will help Inova patients, their family members, and their physicians make more informed decisions about disease prevention and treatment, lifestyle, and diet," said Todd Stottlemyer, CEO of the Inova Center for Personalized Health. "Plus, as advances in research and medicine are made, they will receive valuable updates relevant to their genetic blueprint. It's a long-term investment in their quality of life."